Recombinant Human Growth Hormone Included in Guangdong Alliance Centralized Volume-Based Procurement

On the 23rd, the Guangdong Provincial Drug Exchange Center released a notice regarding the review of relevant information on the registration products for the first batch of centralized volume procurement of diclofenac and other drugs in the Guangdong Alliance. According to the aforementioned notice, among the registration products that meet the declaration conditions for the first batch of the alliance procurement, there are multiple specifications of recombinant growth hormone.

Source of the image: Screenshot from the official website of Guangdong Provincial Drug Exchange Center

According to the notice issued earlier by the Guangdong Provincial Drug Trading Center regarding the "Centralized Bulk Procurement Document for Diclofenac and Other Drugs in the Guangdong Alliance," several recombinant human growth hormones have been included in the centralized procurement list.

The alliance regions include Guangdong, Shanxi, Jiangxi, Henan, Guangxi, Hainan, Guizhou, Qinghai, Ningxia, Xinjiang, and the Xinjiang Production and Construction Corps.

The application information released this time shows that the companies applying for growth hormone powder injections include ANKEBIO, GenSci, Shanghai United Cell Biotechnology Co., Ltd., and Zhongshan Hygene Biopharm Co., Ltd. The multinational pharmaceutical company Novo Nordisk has applied for its recombinant human growth hormone injection product.